Skip to main content

Insmed

Insmed Incorporated is an American biopharmaceutical company focused on developing and commercializing therapies for patients suffering from serious and rare pulmonary diseases. The company's primary commercial product is Arikayce, an liposomal inhaled amikacin formulation approved for refractory Mycobacterium avium complex lung disease. Additionally, Insmed advances a clinical research pipeline targeting bronchiectasis, pulmonary arterial hypertension, and inflammation-driven rare conditions. Its primary revenue drivers stem from product sales of Arikayce to specialty pharmacies, healthcare systems, and pharmaceutical distributors. Insmed holds a specialized market position within the global orphan lung disease sector, targeting unmet medical needs in pulmonology. The primary geographic end markets for its approved products and clinical trials include the United States, Europe, and Japan. Corporate headquarters are situated in Bridgewater, New Jersey, United States. Insmed's common stock is listed on the Nasdaq Global Select Market.

51 of the funds FundTelligence covers report a position in Insmed.

Legal name
Insmed Inc.
Sector
Health Care
Country
United States
Funds holding it
51
Exposure themes
Respiratory and rare diseases, Treatment, Women's Health

Funds holding Insmed

Showing the 8 largest of 51 funds holding it.

Loading...